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ABSTRACT 
 
OBJECTIVE: Hypertrophic cardiomyopathy (HCM) is the most common heart disease in cats and 
causes left ventricular (LV) myocardial hypertrophy and diastolic dysfunction. Apart from the LV, 
the right ventricle (RV) can also be involved depending upon the severity of the disease. 
Pulmonary hypertension (PH) can be a complication of HCM and this pathology is not well studied 
in cats. Therefore, the aim of this work was to evaluate RV function and to determine the 
prevalence of PH in cats with HCM. 
MATERIALS AND METHODS: This prospective echocardiographic study included 25 cats (12 males 
and 13 females) of various breeds (European Shorthair, Persian, Sphynx, Siamese), between 4 
months and 20 years of age (average 6.5 years), weighing between 2.300-5.350 Kg (average 
3.600 Kg). Echocardiographic indices that evaluated the LV and RV were measured in control 
cats (n=7), cats with subclinical HCM (asymptomatic HCM; n=9), and cats with HCM and 
congestive heart failure (HCM + CHF group; n=9). 
RESULTS: Right heart size (RVFWd) was significantly (P < 0.05) increased in HCM+CHF 
compared to control group and several parameters of RV function (FAC, FS and TAPSE) were 
significantly (P < 0.05) decreased in the HCM + CHF group compared with the asymptomatic 
HCM group. PH was present in 2 of the 9 cats with CHF secondary to HCM. 
CONCLUSION: The results support the involvement of the RV in some cases of feline HCM and 
enhance the importance of RV echocardiographic evaluation in cats with HCM. PH is present in 
some cats with HCM+CHF but further studies are required to clarify the results and the usefulness 
of the echocardiographic parameters that were used to assess the presence of PH in cats. 
ii 
 
RESUMO 
 
OBJETIVO: A cardiomiopatia hipertrófica (CMH) é a doença cardíaca mais comum em gatos e é 
caracterizada pela presença de hipertrofia miocárdica do ventrículo esquerdo (VE) e disfunção 
diastólica. O ventrículo direito (VD) pode também estar envolvido, dependendo da gravidade da 
doença. A hipertensão pulmonar (HP) pode surgir como uma complicação da CMH, embora 
ainda não se encontre bem descrita em gatos. O objetivo deste trabalho foi avaliar a função do 
VD e determinar a prevalência de HP em gatos com CMH. 
MATERIAIS E MÉTODOS: Este estudo ecocardiográfico prospetivo incluiu 25 gatos (12 machos e 13 
fêmeas) de várias raças (Europeu comum, Persa, Sphynx, Siamês), entre os 4 meses e os 20 
anos de idade (média de 6,5 anos), com um peso entre os 2.300-5.350 Kg (média de 3.600 Kg). 
O estudo ecocardiográfico da função do VE e VD foi realizado em gatos controlo (n=7), com CMH 
assintomática (n=9) e com CMH e insuficiência cardíaca congestiva (ICC) (n=9). 
RESULTADOS: O tamanho do coração direito inferido pela medição da parede posterior do VD em 
telediástole (RVFWd) estava significativamente (P < 0.05) aumentado no grupo com CMH e ICC 
comparativamente com o grupo controlo. Vários parâmetros que avaliam a função VD 
(percentagem de variação fracionária (FAC), fração de encurtamento (FS) e excursão sistólica 
do plano do anel tricúspide (TAPSE)) estavam significativamente (P < 0.05) diminuídos no grupo 
com CMH e ICC comparativamente com o grupo com CMH assintomática. Foi diagnosticada a 
presença de HP em 2 dos 9 gatos com CMH e ICC. 
CONCLUSÃO: Os resultados suportam o envolvimento VD em alguns casos de CMH e realçam a 
importância da avaliação ecocardiográfica desta câmara cardíaca em gatos com CMH. A HP 
ocorre em alguns gatos com CMH e ICC, mas estudos adicionais são necessários para clarificar 
os resultados obtidos e verificar a utilidade dos parâmetros ecocardiográficos utilizados para 
avaliar a presença HP em gatos. 
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I. INTRODUCTION 
 
My curricular internship of the master degree in veterinary medicine was performed in 
Hospital Veterinário do Porto (HVP) and Davies Referrals, UK. In HVP, I could be part of the 
hospital clinical activity doing weekly rotations in first opinion and referral appointments, 
internment and critical care and surgery. I also did night shifts. In Davies Referrals I was in the 
anaesthesia department where I worked with specialists in the selection of anaesthetics to use in 
different situations, in monitoring of the anaesthesia parameters in different surgeries and while 
they performed imaging techniques. I was also in the cardiology department where I was part of 
their clinical activity, namely appointments, surgeries and complementary diagnostic exams like 
echocardiography and Holter monitoring. The objective of these internships was to improve the 
theoretical knowledge that I earned during my degree and to develop my practical skills in different 
areas of companion animal medicine. 
Simultaneously, I integrated an investigation in which objective was to assess right 
ventricular function and pulmonary hypertension prevalence in cats with hypertrophic 
cardiomyopathy. The echocardiographic studies were performed in the HVP by Doctor Luís Lima 
Lobo according to the echocardiographic standards for transthoracic echocardiography of the 
American College of Veterinary Internal Medicine (Thomas et al., 1993). The echocardiographic 
indices were chosen based on literature from human and veterinary medicine (mainly cats and 
dogs) in the fields of hypertrophic cardiomyopathy, pulmonary hypertension and 
echocardiographic examination of heart function. 
More specifically, the objective of this study was to estimate the number of cats with HCM 
that are affected with PH and to assess RV function and its involvement in this pathology. 
Considering the lack of studies in cats that relate both pathologies, as well as recognizing the 
importance of echocardiographic evaluation, this work highly contributes to the improvement of 
the knowledge about these pathologies and, also, to highlight the importance of right ventricular 
function assessment in cats with HCM. 
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II. STATE OF THE ART 
1. FELINE HYPERTROPHIC CARDIOMYOPATHY  
1.1. Definition  
A cardiomyopathy can be defined as a heterogeneous class of disorders in which there is 
a structural abnormality and functional impairment of the heart muscle. Therefore, it excludes 
hypertensive, vascular, valvular, pericardial, pulmonary, metabolic or congenital disorders (Fox 
et al., 1999). Cardiomyopathies can be classified as primary (idiopathic) cardiomyopathy when 
the heart disease results from an inherent problem in the myocardium and when the aetiology 
cannot be identified (Fox et al., 1999). In secondary cardiomyopathies, the myocardial 
involvement is a result of multiorgan systemic disorders (Smith et al., 2016). 
Hypertrophic cardiomyopathy (HCM) is one of the four types of idiopathic heart muscle 
diseases and is characterized by a hypertrophied, nondilated (primarily left) ventricular 
myocardium in the absence of other cardiac, systemic or metabolic abnormalities that can 
produce the same magnitude of hypertrophy (Fox et al.,1999). 
1.2. Aetiology 
HCM is the most common heart disease in cats and although the disease is known to be 
inherited in some breeds, in most cases it is idiopathic (Abbott, 2010). HCM is a heritable disease 
in breeds like the Maine coon, Ragdoll, American shorthair (Côté et al., 2011) and has also been 
described in Persian, Norwegian Forest, Sphynx and mixed-breed cats. Although inherited in 
some breeds, HCM is not a congenital disease; it develops with age and can occur at any time 
during life span (Häggström et al., 2015). 
In Maine Coon and Ragdoll cats, HCM is an autosomal dominant inherited disease and a 
myosin binding protein C gene (MYBPC3) mutation has been identified in some cats (Côté et al., 
2011). However, some Maine Coon cats with myocardial hypertrophy do not have this mutation, 
suggesting that other causative mutations may exist or that there is a non-genetic cause of HCM 
in this breed (Häggström et al., 2015). 
1.3. Pathophysiology 
Understanding the genetic mutations leading to the development of hypertrophy has been 
a difficult task, since their precise mechanisms have not been fully described (Abbott, 2010). 
However, it is known that in this type of cardiomyopathy, some changes occur in sarcomeric 
proteins of cardiomyocytes responsible for cardiomyocyte dysfunction. This dysfunction induces 
cell stress responses, which increase cell transcription and result in the cardiomyocyte 
hypertrophy, increased collagen formation and myofiber disarray that typifies the final HCM 
phenotype. This phenotype is characterized by a concentric left ventricle (LV) hypertrophy, 
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myocardial fibrosis, and myofiber disarray, which leads to diastolic and possibly systolic 
dysfunction (Côté et al., 2011). 
The main pathophysiologic feature of HCM is diastolic dysfunction, due to impaired 
diastolic filling of the LV caused by a non-uniform relaxation of the myocardium and increased 
stiffness (abnormal distensibility) of the ventricular muscle (Fox et al.,1999). The altered pattern 
of myocardial relaxation can be explained by increased myofilament sensitivity to calcium, 
intracytosolic calcium overload, changes in LV loading conditions and myocardial ischemia due 
to small coronary artery remodelling. The ventricular stiffness is augmented by concentric LV 
hypertrophy, myofiber disarray and myocardial fibrosis (Côté et al., 2011). 
The diastolic dysfunction results in a ventricle that cannot properly fill with blood during 
diastole, leading to an increased LV diastolic filling pressure (White, 2015); in turn this is 
responsible for LA dilation, and elevation of its pressure, that consequently promotes elevated 
pressure in the pulmonary veins. When the LV diastolic filling pressure and pulmonary venous 
pressure exceed approximately 24 mm Hg (Côté et al., 2011), left sided congestive heart failure 
(CHF) occurs with the development of cardiogenic pulmonary oedema and/or pleural effusion 
(Smith et al., 2016). LA enlargement also increases the risk of thrombus formation (White, 2015) 
because it causes blood flow stasis, which results in erythrocyte aggregation and platelet 
activation (Côté et al., 2011). The thrombus can then break loose (become an embolus) and most 
commonly lodges in the terminal aorta, causing aortic arterial thromboembolism (ATE) (Smith et 
al., 2016). 
The diastole is the most affected phase of the cardiac cycle in cats with HCM, although in 
some cases, systolic abnormalities like systolic anterior motion (SAM) of the mitral valve and 
consequently LV outflow tract obstruction (LVOTO) may be present (Fox et al.,1999). The anterior 
motion of the mitral valve toward the interventricular septum (IVS) during systole occurs 
secondary to displaced, hypertrophied papillary muscles that pull the mitral valve into the LV 
outﬂow tract (LVOT) and thus causes LVOTO (Côté et al., 2011). Due to this displacement of the 
valve, mitral regurgitation (MR) can occur. The obstruction of the LV outflow tract caused by SAM 
leads to increased LV work, with impeded and turbulent ejection of blood flow throw the aortic 
valve, which may result in a murmur. It is important to mention that is not an intrinsic feature of 
HCM in cats, but when SAM is echocardiographically identified it is highly suggestive for the 
diagnosis of HCM (Luis Fuentes and Wilkie, 2017). 
1.4. Clinical signs  
Around half of the cats with HCM are asymptomatic and diagnosed incidentally on routine 
physical examination when a heart murmur or a gallop heart sound is auscultated (Côté et al., 
2011). The most common auscultation finding in HCM is a systolic murmur (36–72% of cats) 
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(Smith et al., 2016), often associated with dynamic LVOTO (Luis Fuentes and Wilkie, 2017), 
followed by a gallop heart sound (33% of cats) (Smith et al., 2016). The gallop heart sound is a 
much more specific finding of HCM and generally reflects diastolic dysfunction (Luis Fuentes and 
Wilkie, 2017). Arrhythmias are a rare finding in cats with HCM (7%) (Smith et al., 2016). 
Of those cats with CHF due to HCM, half had a triggering event such as fluid therapy, 
anaesthesia and surgery, or corticosteroid administration (Côté et al., 2011). There are some 
exceptions, as with early stages of decompensation when the owners may observe tachypnoea. 
However, cats with CHF usually exhibit peracute (in less than 24 hours) clinical signs associated 
with pulmonary oedema and/or pleural effusion (Fox et al.,1999). Dyspnoea is the most common 
sign (32–46% of cats) (Smith et al., 2016), but cough is rarely observed in cats with CHF. 
Lethargy, anorexia and vomiting may precede respiratory signs by 1 or 2 days in some cats. In 
the case of a significant pleural effusion, heart and lung sounds will be muffled (Fox et al.,1999). 
Syncope is less common (4%), and it may result from an arrhythmia, severe CHF, an intracardiac 
thrombus (Côté et al., 2011) or LVOTO (Fox et al.,1999). Sudden unexpected death as the first 
clinical manifestation of this disease may occur in few cats (Abbott, 2010). 
ATE secondary to HCM occurs in approximately 12% to 17% of cats and causes a 
cessation of blood flow more commonly to the caudal legs (Smith et al., 2016). However 
occasionally paresis of one front leg (generally the right one) may occur (Fox et al.,1999). Cats 
with a thrombus in the aorta show acute clinical signs like acute paresis/paralysis, lameness and 
acute pain (Smith et al., 2016), while front leg paresis seems to be better tolerated (Fox et 
al.,1999). 
1.5. Diagnoses 
Echocardiographic examination is the gold-standard method to diagnose HCM in cats 
(Abbott, 2010). It allows the assessment of systolic and diastolic myocardial function and chamber 
dimensions, quantification of concentric hypertrophy, identification of spontaneous echo contrast 
or an intracardiac thrombus and evaluation of the origin of a murmur (Côté et al., 2011). Cats with 
HCM can have different phenotypes of hypertrophy: generalized concentric hypertrophy, 
asymmetric (segmental) concentric hypertrophy of the septum or free wall or papillary muscle 
hypertrophy (Smith et al., 2016). 
The diagnosis of HCM is established when there is an increased end-diastolic LV wall 
thickness in two-dimensional (B-mode) of 6 mm or greater in the absence of other secondary 
causes of concentric hypertrophy. The cut-off value (6 mm) is likely representative of a marker of 
HCM (Luis Fuentes and Wilkie, 2017) and there is an equivocal zone (cats suspected of HCM) 
from 5.5–5.9 mm. It is also important to mention that HCM can be classified, according with LV 
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wall thickness, as mild (6-6.5 mm), moderate (6.6–7.5 mm), and severe (>7.5 mm) (Côté et al., 
2011). 
LA size can be measured by B-Mode and Motion-mode (M-mode), and LA dilation is 
identified when the LA diameter to aortic diameter ratio on M-mode is >1.6 (Visser, 2017). SAM 
of the mitral valve can be identified on B-mode echocardiography from the right parasternal long-
axis LVOT view. Therefore, continuous-wave Doppler may easily detect this abnormality because 
it shows a turbulent double jet of MR and turbulence in the LVOT arising from the common point 
of the anterior mitral leaﬂet obstruction (Côté et al., 2011). To quantify the severity of the 
obstruction, velocity of aortic blood flow can be estimated from the left apical parasternal 5-
chamber view using continuous-wave Doppler (Smith et al., 2016). 
Diastolic function can be evaluated using pulsed-wave Doppler to quantify mitral inﬂow 
velocity from the left apical four-chamber view that often, in cats with HCM, shows a delayed 
relaxation pattern: decreased early diastolic mitral velocity (E), increased late diastolic mitral 
velocity (A) which causes a reversed E/A ratio of <1, prolonged isovolumetric relaxation time, and 
prolonged deceleration time of the early diastolic mitral velocity. This delayed relaxation 
corresponds to the first level of diastolic dysfunction when there is an impaired early diastolic 
filling but normal LA pressures. As diastolic dysfunction worsens, LA pressure increases, leading 
to a pseudo-normal filling pattern of mitral inﬂow velocity. Then, when the dysfunction is severe, 
and the atrial pressure is significantly increased, a restrictive filling pattern is seen: increased 
early diastolic filling (E), decreased late diastolic filling (A), E/A ratio >2, decreased deceleration 
time, and shortened isovolumetric relaxation time (Smith et al., 2016). 
Thoracic radiographs also provide valuable information about the size of the heart and 
pulmonary parenchymal and vascular changes (Fox et al.,1999), helping to identify the 
manifestations of CHF in cats with HCM, and to monitor response to treatment. Abnormalities like 
cardiomegaly, LA dilation, pulmonary venous distension, diffused patchy interstitial to alveolar 
pulmonary infiltrates (pulmonary oedema) and obscured cardiac silhouette (pleural effusion) are 
potential radiographic findings. However, sometimes the size of the heart may be normal in cats 
with mild HCM because of the concentric pattern of hypertrophy (Côté et al., 2011). An additional 
sensitive and accurate screening test to detect HCM in cats is the biomarker N-terminal pro-brain 
natriuretic peptide (NT-proBNP) that is released from the ventricles when the myocardium is 
stretched (White, 2015). It also helps to differentiate the origin of dyspnoea (CHF secondary to 
HCM or primary respiratory disease) (Côté et al., 2011) and to detect asymptomatic HCM, but 
there may be false negatives and positives (Côté et al., 2011). 
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1.6. Treatment 
In asymptomatic cats with HCM and no CHF there is no consensus on when to start 
treatment and what is the most appropriate therapy (Côté et al., 2011). The main goals are to 
reduce LV hypertrophy, to improve diastolic function, to reduce the risk of ATE and to increase 
the time to heart failure. The decision to treat should be focused on severity of SAM of the mitral 
valve and left ventricular hypertrophy, size of the LA, presence of tachyarrhythmias, compliance 
of the owner to medicate daily to twice daily indefinitely and the cat’s temperament (Smith et al., 
2016). 
Beta-blockers (e.g. atenolol) and calcium channel blockers (e.g. diltiazem) are the drugs 
most commonly used in asymptomatic cats and they may reduce myocardial hypertrophy. Beta-
blockers are more effective in reducing the severity of SAM than calcium channel blockers and 
help to prevent tachycardia. Administration of angiotensin converting enzyme (ACE) inhibitors or 
aldosterone antagonists in asymptomatic cats is not warranted. If there is evidence of 
spontaneous contrast, an intracardiac thrombus, or moderate to severe LA dilation, anticoagulant 
therapy such as clopidogrel is indicated (Smith et al., 2016). 
The most common emergencies in symptomatic HCM cats include left-sided heart failure 
(pulmonary oedema and/or pleural effusion) and ATE (Smith et al., 2016). In cases of left-sided 
heart failure, the diuretic furosemide can be life-saving by reducing pulmonary oedema and 
slowing accumulation of pleural effusion. Parenteral furosemide should be administered and then 
the dose and frequency adjusted once the respiratory rate decreases to ≤50 breaths/minute and 
the respiratory effort decreases (Côté et al., 2011). Oxygen therapy is also beneficial (Fox et al., 
1999), and in cats with respiratory distress due to severe pleural effusion, thoracocentesis is 
required to stabilize the patient (Fox et al., 1999). Once stabilized, the animal should be started 
on long-term treatment to maintain cardiac compensation, prevent ATE and improve myocardial 
function and quality of life (Fox et al., 1999). 
Diuretics are the gold-standard treatment in chronic heart failure management and in cats 
stable enough oral furosemide can be administered; however, it is important to assess kidney 
function before starting long-term furosemide (Côté et al., 2011). The addition of an ACE inhibitor 
(e.g. enalapril or benazepril) is also a standard approach once the cat is stable (Smith et al., 2016) 
because neurohormonal activation plays an important role in heart failure (Fox et al., 1999). 
Negative inotropic therapy (e.g. beta-blockers and calcium channel blockers) may be used in 
some cats with chronic heart failure. Also, prophylactic anticoagulant therapy may be started in 
cats with high risk of ATE (Côté et al., 2011). 
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1.7. Pulmonary Hypertension 
1.7.1. Definition and Classification 
Pulmonary hypertension (PH) can be defined as a pathologic condition resulting from an 
abnormally high pressure in the pulmonary circulation (Vezzosi et al., 2018) and can be classified 
as a primary disease (idiopathic) or more often a secondary disease (Pyle and Abbott, 2004). 
Then, depending on the anatomic location of the pulmonary vascular system affected it can be 
classified as pulmonary arterial hypertension (PAH) or pre-capillary or active if it affects the arterial 
side, or pulmonary venous hypertension (PVH) or post-capillary or passive if it occurs on the 
venous side (Kellihan and Stepien, 2012). In human medicine, PH can also be classified using a 
five-group system depending on the causative pathological process. The five groups are: I (PAH 
due to arteriolar vascular disease), II (PVH due to left heart disease), III (PH with chronic lung 
disease and/or hypoxia, IV (chronic thromboembolic pulmonary hypertension) and V (PH from 
unclear or multifactorial mechanisms) (Galiè et al., 2016). 
1.7.2. Pulmonary Hypertension secondary to Hypertrophic Cardiomyopathy 
In humans with HCM, PH can be a complication of elevated left-sided (LV and LA) diastolic 
pressures secondary to diastolic dysfunction (impaired relaxation and stiffness of the 
myocardium), LVOTO with MR or even systolic dysfunction that happens in end stages of HCM 
(Musumeci et al., 2017). This elevated LV filling pressure is passively back-transmitted to the 
pulmonary capillaries causing PH (Vezzosi et al., 2018). Although evidence of feline PH is limited 
to case reports (Ettinger et al., 2017), the same assumption may be extrapolated to cats with 
HCM. 
Patients with left-sided heart disease may have concurrent PVH and PAH. PVH is caused 
by a combination of hypertension from increased LA pressures and reactive pulmonary arterial 
vasoconstriction due to acute or chronic hypoxia (caused by pulmonary oedema) (Kellihan and 
Stepien, 2012). PAH secondary to LA hypertension (LAH) occurs in the continuum of progression 
of heart disease to heart failure. LAH is associated with neurohormonal activation of the 
sympathetic nervous system, the renin-angiotensin-aldosterone system, and augmented activity 
of endothelin-1 (ET-1) (potent arterial vasoconstrictor), phosphodiesterase-5 (PDE 5) and 
natriuretic peptides (NP) that results in pulmonary arterial vasoconstriction (hypertension) 
(Stepien, 2009). In humans with HCM, PH is also associated with increased mortality (Ong et al., 
2016). 
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1.7.3. Clinical signs and Diagnosis 
The clinical signs of PAH can be similar to signs of left-sided CHF or may not be noticeable 
if signs of right-sided CHF are not present (Stepien, 2009). Murmurs of tricuspid or pulmonic 
insufficiency can be detected during systole or diastole respectively (Johnson, 2010). 
In veterinary medicine, PH is more commonly diagnosed in dogs than in cats (Nelson and 
Couto, 2013) and echocardiography has replaced cardiac catheterization as a diagnostic 
approach for PH because it provides alternative values for many previously invasively measured 
parameters obtained by right heart catheterization. In combination with other tests it is possible 
to diagnose the presence and possible causes of PH (Stepien, 2009). There are multiple B-
dimensional echocardiographic findings that are used to support the diagnosis of PH, including 
RV hypertrophy (due to acute and chronic RV pressure overload), septal flattening (when RV 
pressure approaches or exceeds LV pressure) and pulmonary arterial dilation (Kellihan and 
Stepien, 2012).  
In dogs, a tricuspid regurgitation pressure gradient (TRPG) ≥ 36 mmHg (Vezzosi et al., 
2018) or pulmonic insufficiency (PI) by Doppler echocardiography (Kellihan and Stepien, 2012) 
allows an estimation of pulmonary arterial pressure in systole (PAPs) and thus the identification 
of PH (Stepien, 2009). The TRPG is derived from the peak systolic regurgitation jet velocity using 
the modified Bernoulli equation: Pressure gradient (PG) = 4 × (peak TR velocity)2. Then, based 
on TRPG values, it is possible to classify dog’s PAH as mild (36-50 mmHg), moderate (51-75 
mmHg) and severe ( 75 mmHg) (Vezzosi et al., 2018). 
A study in dogs infected with heartworms and another that studied PH in dogs reported 
that right pulmonary artery distensibility index (RPADi) is a valuable method for early detection of 
the presence and severity of PH even when Doppler echocardiography does not show TR or PI 
(Visser et al., 2016; Venco et al., 2014). Venco et al. (2014) also demonstrated that RPADi has a 
strong correlation with invasive “gold standard” systolic PA pressures and it might be valuable to 
start applying this method in combination with TRPG to diagnose PH. To calculate RPADi, the 
right pulmonary artery (PA) is the one chosen because it is usually affected earlier and to a greater 
degree. Taking into account that the walls of PA distend when the blood pressure increases during 
systole and recoil when the blood pressure diminishes during diastole (Venco et al., 2014), RPADi 
is calculated by M-mode as the difference in diameter of the pulmonary artery in systole and 
diastole by the following formula: RPADi = (Pas - PAd)/Pas × 100  (Serrano-Parreño et al., 2017). 
In dogs, a normal pulmonary pressure is correlated with a RPADi ≥36% (Serrano-Parreño et al., 
2017) and a RPADi < 35% is indicative of PH. Then, RPADi between 35%-28% is correlated with 
mild PH (30–55 mm Hg), between 27%-23% with moderate PH (56–79 mm Hg) and less than 
22% with severe HP (>79 mm Hg) (Venco et al., 2014). 
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1.7.4. Treatment  
The objectives of therapy for PAH due to left-heart disease are to improve haemodynamic 
status and clinical signs. These aims are achieved through reduction of PVH (managing LA 
hypertension) and reactive PAH that may be present in addition to PVH (using pulmonary 
vasodilators) (Stepien, 2009) and improving LV systolic and diastolic function (Kellihan and 
Stepien, 2012). 
To reduce LA pressure combining diuretics (e.g. furosemide or torsemide) and optimal 
neurohormonal blockade (e.g. aldosterone blockade, ACE inhibition and beta-blockers) is a good 
approach. Reactive PAH can be diminished by using pulmonary vasodilators such as ET-1 
antagonists, PDE-5 inhibitors and calcium-sensitizing phosphodiesterase-3 (PDE-3) inhibitors 
(Stepien, 2009). ET-1 antagonists (e.g., bosentan) promote pulmonary and systemic vasodilation 
but costs are prohibitive in veterinary medicine (Ettinger et al., 2017). PDE-5 inhibitors are 
pulmonary arterial vasodilators (mainly large arteries) and the most common drug of this class is 
sildenafil citrate (Stepien, 2009). Sildenafil is used in dogs since it diminishes clinical signs of PH 
and improves quality of life (Ettinger et al., 2017). In cats, there is little information available 
(Ramsey, 2017), with only one reported case of a cat with PH caused by a left-to-right shunt, 
where sildenafil was used (Novo-Matos et al., 2014). The PDE-3 inhibitors and also calcium 
sensitizing agents (e.g. pimobendan) differ from PDE-5 inhibitors because they vasodilate both 
large and resistance pulmonary arteries and the positive inotropic effects may result in decreased 
LA pressures (Stepien, 2009). The calcium-sensitizing PDE-3 inhibitors (pimobendan) and PDE-
5 inhibitors (sildenafil) are the most often used pulmonary vasodilators in dogs (Kellihan and 
Stepien, 2012), either separately or in combination, and are the most promising for therapy of 
PAH associated with left heart dysfunction (Stepien, 2009). 
2. RIGHT VENTRICULAR FUNCTION 
2.1. The Importance of Right Ventricle in Feline Hypertrophic Cardiomyopathy 
In veterinary medicine, the quantitative assessment of RV function is not well studied and 
most of the time is not properly evaluated during routine clinical echocardiographic assessment 
(Visser, 2017). This might be explained by two main reasons: (i) the RV seems to be less 
commonly or obviously involved in cardiovascular diseases and (ii) its function is difficult to 
quantify compared with the LV due to the complexity of its three-dimensional shape, separate 
inflow and outflow regions, prominent endocardial trabeculations and marked load-dependence 
(Visser, 2017; Voelkel et al., 2006). In human medicine, the importance of quantitative RV function 
assessment as a predictor of clinical status, morbidity, and mortality is well recognized in cardiac 
diseases that also affect dogs and cats, including those regarded as left-heart specific, such as 
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mitral valve disease and HCM which enhance ventricular function as a single unit (Visser, 2017; 
Haddad et al., 2008). 
Previous studies in cats with HCM that evaluated RV size and function documented that 
remodelling and dysfunction occurs in some cats with HCM and may be associated with clinical 
status and severity (Visser et al., 2017; Schober et al., 2016). Other recent studies in cats with 
HCM reported that increased RV wall thickness is common in cats with HCM and related to LV 
hypertrophy severity (Spalla et al., 2017). RV hypertrophy is also associated with increased risk 
of CHF, ATE, ventricular tachyarrhythmias and sudden death (Visser et al., 2017). The main 
mechanisms by which cats with LV dysfunction develop abnormal RV function and dilatation are: 
(i) PVH with subsequent PAH and (ii) as a consequence of the hypertrophic cardiomyopathic 
process involving the RV (Visser et all., 2017; Voelkel et al., 2006). 
2.2. Assessment of Right Ventricular Function  
The most practical method for quantitative assessment of RV function in cats is 
echocardiography (Visser, 2017). There are several echocardiographic indices that can be 
measured and the ones acquired from the left apical 4-chamber view optimized for the right heart 
are: Tricuspid annular plane systolic excursion (TAPSE), RV-Myocardial performance index (RV-
MPI), RV fractional area change (FAC) and Tissue Doppler imaging derived peak systolic (TDI 
RVFW S’), early diastolic (TDI RVFW E), late diastolic (TDI RVFW A) RV wall myocardial velocity 
of the lateral tricuspid annulus (Visser, 2017). Other important indices obtained from the right 
parasternal long-axis 4-chamber view are: Maximum right atrial diameter (RAD), RV internal 
dimension (RVID), RV fractional shortening (RVFS) and the thickest portion of the RV free wall at 
end-diastole (RVFWd) (Visser et al., 2017). 
The TAPSE measurement consists of quantifying the maximal longitudinal displacement 
of the lateral tricuspid valve annulus towards the RV apex during systole (Visser, 2017) and is 
obtained from M-mode with the cursor over the tricuspid annulus (Boon, 2011). It is a marker of 
RV longitudinal systolic function and is lower in cats with HCM compared with healthy cats, 
confirming reduced systolic function possibly due to concomitant RV cardiomyopathy or PH 
secondary to left-sided disease (Spalla et al., 2017). In cats with HCM, reduced TAPSE is 
negatively associated with the severity and survival times. In most dogs, TAPSE is decreased 
with severe PH (Visser, 2017). 
Measurement of the RV area to determine FAC is obtained by tracing the RV endocardial 
border at end-diastole (RVAd) and end-systole (RVAs). Then, FAC is calculated using the 
following formula: FAC = (RVAd - RVAs)/RVAd × 100 (Visser, 2017). FAC is a surrogate of RV 
ejection fraction and is decreased in dogs (Visser, 2017) and in humans with  severe PH (Boon, 
2011). 
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B-mode pulsed-wave TDI of the lateral tricuspid annulus allows the assessment of RV 
myocardial systolic and diastolic function. In humans, decreased TDI RVFW S’ is associated with 
decreased RV ejection fraction (Boon, 2011; Cincin et al., 2015). In cats with HCM, the TDI LVFW 
could detect LVFW dysfunction (Silva et al., 2013). TDI velocities can be reduced for reasons like 
PH and other causes of RV systolic dysfunction (Kellihan and Stepien, 2012). 
The measurement of RAD is made at end-systole from the middle of the interatrial septum 
to the right atrial lateral wall in a cranial-caudal plane and parallel to the tricuspid valve annulus. 
RVID is measured at end-diastole (RVIDd) and end-systole (RVIDs) at the level of the RV where 
the tips of the opened tricuspid valve leaflets contact the endomyocardium and parallel to the 
tricuspid valve annulus. Then, RVFS is calculated as RVFS = (RVIDd - RVIDs)/RVIDd × 100. The 
RVFWd is measured at end-diastole from the inner edge of the RV endomyocardium to the outer 
edge of the RV epimyocardium, excluding the pericardium (Visser et al., 2017). 
MPI or Tei index is an index of global (systolic and diastolic) myocardial function of the RV 
and LV (Boon, 2011). To evaluate RV function, this index is measured by pulsed-wave Doppler 
of the tricuspid and pulmonary inflow. Then, MPI is calculated: RV MPI = (IVCT + IVRT)/ET or  
RV MPI = (a-b)/b where “a” represents the time from closure to opening of tricuspid valve and “b” 
represents ejection time of pulmonary artery flow, “ET” is the ejection time, IVCT is isovolumetric 
contraction time and IVRT is isovolumetric relaxation time (Kellihan and Stepien, 2012). 
Augmented values of RV MPI are associated with RV myocardial dysfunction when changes in 
load are chronic (Boon, 2011; Visser, 2017). MPI is also a valuable indicator of PH and increased 
MPI may support the diagnosis of PH. In dogs, a value of >0.25 supports the diagnosis of PH 
(Kellihan and Stepien, 2012). 
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III. OBJECTIVES 
HCM is the most common heart disease diagnosed in cats and there are many studies 
that focus on assessment of LV function. In human medicine, the involvement of the RV in HCM 
has also been described, and as a result there is an increase in the number of studies to assess 
RV function and its importance in HCM in veterinary medicine. In addition, PH has been studied 
in humans with HCM and in dogs with mitral valve disease and heartworm infections, but there is 
a lack of information in cats. 
Therefore, the objective of the following prospective study was to focus on evaluating RV 
function and the prevalence of PH in cats with HCM. The specific objectives for this study were: 
• Evaluate RV function by echocardiography in healthy cats and in cats with HCM 
(asymptomatic and symptomatic); 
• Evaluate the prevalence of PH in cats by applying the echocardiographic indices used 
in dogs and humans; 
• Compare the results obtained for different variables with different studied groups; 
• Compare the results obtained for the different evaluations with the reference intervals 
for dogs and other species; 
• Propose preliminary reference intervals for echocardiographic indices that in the 
literature were evaluated only in dogs (RV MPI and RPADi); 
Learning the fundamentals of echocardiography, indices that can be measured, how to 
measure and to improve the knowledge about HCM and PH were skills also developed during 
this work. Finally, knowledge of statistical analysis and the discussion of the experimental results 
are an important step in the process of scientific learning and a complementary earned skill of my 
masters degree. 
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IV. MATERIALS AND METHODS 
1. FELINE POPULATION CHARACTERIZATION  
Cats were included in this prospective study if they underwent a complete standard 
echocardiographic examination according to human and veterinary guidelines (Thomas et al., 
1993; Lang et al., 2015) with evaluation of left and right sides of the heart, pulmonary artery and 
related heart valves in M-mode, B-mode, and Doppler echocardiography. This echocardiographic 
study was performed in HVP, from September 2017 to March 2018, in 25 cats aged between 4 
months and 20 years. To be included in the study, a complete case record (owner data, cat 
signalment (weight, breed, age, gender, body score), history, clinical signs, cardiac insufficiency 
classification if the animal had CHF (stands for International Small Animal Cardiac Health Council 
(ISACHC) and American College of Veterinary Internal Medicine (ACVIM)), complementary 
exams (type and evidence of pleural effusion (yes/no) or pulmonary oedema (yes/no)), 
concomitant diseases and current medications (type/dose) were required and recorded (see 
Appendix I). 
Cats were chosen only if they met the inclusion criteria and none of the exclusion criteria. 
Control cats had to be apparently healthy (with no clinical signs of systemic diseases), with a 
normal echocardiographic examination (normal myocardial structure and function) and not 
administered any medications that could affect the cardiovascular system. For cats diagnosed 
with HCM, the exclusion criteria included: any concomitant cardiac disease and any systemic 
disease that could affect LV wall thickness such as dehydration or hypovolemia, primary 
respiratory disease, hyperthyroidism, acromegaly, cardiomyopathies other than HCM, congenital 
diseases, neoplastic diseases and systemic hypertension (systolic blood pressure > 170 mmHg). 
In all cats diagnosed with HCM with an age superior to 6 years (high-risk) was dosed serum total 
thyroid hormone (T4) concentrations and measured blood pressures. Cats with MR were included 
only if it was secondary to SAM of the mitral valve. Cats with electrocardiographic alterations like 
sustained or clinically relevant tachy/brady-arrhythmia were also excluded. 
Then, cats were allocated into 1 of 3 groups: (1) control group comprising apparently 
healthy cats with normal echocardiographic indices, (2) asymptomatic HCM group consisting of 
cats with HCM but with no clinical evidence of CHF (3) HCM + CHF group comprising cats with 
HCM and CHF. Cats were allocated to the control group if the end-diastolic LV wall thickness 
measured in B-mode was < 6 mm. Cats with a soft systolic heart murmur were also included in 
this group. Cats were diagnosed with HCM if the end-diastolic (diffused or segmental) LV wall 
thickness measured in B-mode was ≥ 6 mm. Cats with HCM that were not receiving any cardiac 
medication and had no signs or history of increased respiratory rate (tachypnoea) or effort 
(dyspnoea), syncope or ATE were classified as asymptomatic. The criteria used to diagnose CHF 
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were the presence of clinical signs compatible with CHF (tachypnoea, dyspnoea, distended 
jugular veins, ascites, abnormal thoracic auscultation), LA enlargement (diagnosed when LA 
dimension (LAD) >16 mm (Abbott and MacLean, 2006) or LA diameter to aortic diameter ratio on 
M-mode is >1.6 (Visser et al., 2017)), and radiographic or ultrasonographic evidence of pleural 
effusion or radiographic evidence of pulmonary oedema. In this third group of HCM + CHF, cats 
with more than mild pericardial effusion were excluded to ensure that the effects on RV size and 
function were originated only by HCM. 
Cats were also classified based on reference values obtained in dogs (Visser et al., 2016): 
no PH if TRPG was < 36 mmHg and with PH if TRPG was ≥ 36 mmHg on echo-Doppler 
examination. The TRPG was measured based on the peak systolic TR jet velocity using the 
modified Bernoulli equation. The severity of PH was classified as mild if TRPG was between 36-
50 mmHg, moderate if TRPG was between 50-75 mmHg and severe if TRPG was > 75 mmHg 
(Vezzosi et al., 2018; Visser et al., 2016). 
2. ECHOCARDIOGRAPHIC EXAMINATION 
All echocardiographic studies were performed by a single veterinary cardiologist. Cats 
received butorphanol (0.2 mg/kg IM or IV) before echocardiographic examination if sedation was 
required. The echocardiographic measurements were obtained by B-Mode, M-Mode and Doppler 
(pulsed-wave Doppler including color-flow Doppler and pulsed-wave TDI). 
If the thickest portion of the interventricular septum (IVSd) and LV free wall (LVFWd) 
measured at end-diastole from both long-axis (Lx) and short-axis (Sx) images in B-Mode were ≥ 
6 mm at any location, cats were diagnosed with HCM (if no exclusion criteria were met). These 
indices were also measured in end-systole (IVSs and LVFWs). LV internal dimension was 
measured at end-diastole (LVIDd) and end-systole (LVIDs) from the right parasternal Sx view. 
Then, LV fractional shortening (LVFS) was calculated as (LVIDd - LVIDs)/LVIDd × 100 (Visser et 
al., 2017). LAD and left atrium-to-aorta ratio (LAD/Ao) were measured by M-mode from right 
parasternal Lx view, LAD at end-systole and the aortic diameter at the end-diastole. Then, LAD/Ao 
was derived from these dimensions (Abbott and MacLean, 2006). A LAD/Ao >1.6 was used to 
determine LA dilation (Visser et al., 2017). LV ejection fraction (LV EF) was automatically 
measured by the ultrasound machine according to the Teichholz formula (Arora et al., 2010). The 
MAPSE IVS was measured by M-mode from the left apical 4-chamber view, with the cursor 
parallel to the IVS between the most basilar position of the mitral annulus in end-diastole and its 
most apical displacement at end-systole by the leading-edge method (Spalla et al., 2017). 
Mitral valve and tricuspid valve peak flow velocity in early and late diastole were also 
measured using pulsed-wave and color-flow Doppler from the left parasternal 4-chamber view 
and the respective gradients were calculated using the simplified Bernoulli equation: PG = 4 × 
15 
 
(peak velocity)2 (Boon, 2011). Aortic valve peak flow velocity (Ao) was also measured using the 
left parasternal apical 5-chamber view and pulmonary valve peak flow velocity (Pulm) was 
measured using the right parasternal 4-chamber view, both using pulsed-wave and color-flow 
Doppler and the respective gradients were calculated using the simplified Bernoulli equation: 
PG = 4 × (peak velocity)2 (Boon, 2011). 
On the right side of the heart, several indices (RAD, RVID and RVFWd) were obtained 
from a right parasternal Lx 4-chamber view (Schober et al., 2016), and TAPSE, FAC and pulsed-
wave TDI velocities of longitudinal RVFW myocardium were acquired from a left apical 4-chamber 
view (Visser et al., 2017). RAD was obtained at end-systole (RADs) and end-diastole (RADd) 
from the mid-point of the interatrial septum to the right atrial (RA) lateral wall in a cranial-caudal 
plane and aligned to the tricuspid valve annulus. RVID was measured at end-systole (RVIDs) and 
end-diastole (RVIDd) where the tips of the opened tricuspid valve leaflets contact with the RV 
endomyocardium and parallel to the tricuspid valve annulus. Then, RV FS was calculated as 
RVFS = (RVIDd-RVIDs)/RVIDd × 100. The presence of RV hypertrophy was estimated through 
the measurement of RVFW diameter at end-diastole (RVFWd) from the inner edge of the RV 
endomyocardium to the outer edge of the RV epimyocardium without including the pericardium 
(leading edge to trailing edge method) (Visser et al., 2017; Schober et al., 2016). A value higher 
than the maximum of RVFWd in healthy cats was used to identify the presence of RV hypertrophy. 
RVFWd was also indexed to body weight (iRVFW) in kilograms using the formula: iRVFWd = 
RVFWd/(body weight0.33). FAC was calculated tracing the RV area of the RV endomyocardial 
border at end-diastole (RVAd) and end-systole (RVAs) excluding the papillary muscle and 
applying the following formula: FAC = (RVAd - RVAs)/RVAd × 100 (Visser et al., 2017). The 
TAPSE were measured by M-mode from the left apical 4-chamber view optimized for the RV, with 
the cursor as parallel as possible to the RVFW between the most basilar position of the tricuspid 
annulus in end-diastole and its most apical displacement at end-systole by the leading-edge 
method (Spalla et al., 2017; Visser, 2017) (Figure 1) (See Appendix V). 
The pulsed-wave TDI velocities of longitudinal myocardial motion at the lateral tricuspid 
annulus were obtained by aligning the cursor as parallel as possible to the RVFW to measure 
peak systolic annular velocity (TDI RVFW S’) (Visser et al., 2015), and peak early (TDI RVFW E) 
and late (TDI RVFW A) diastolic annular velocities (Kellihan and Stepien, 2012). Then the 
respective gradients were calculated using the simplified Bernoulli equation: TRPG= 4 × (peak 
velocity)2 (See Appendix V). RV MPI was calculated using pulsed-wave Doppler (Kellihan and 
Stepien, 2012), to measure the tricuspid inflow time (time between the opening and closure of 
tricuspid valve) and the pulmonary ejection time via pulsed-wave Doppler in order to apply the 
following formula: RV MPI = (x-ET)/ET where “x” represents the time from closure (cessation of 
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A wave) to opening (beginning of E wave) of the tricuspid valve and “ET” represents ejection time 
of pulmonary artery flow (Visser, 2017) (See Appendix V). 
Peak systolic TR jet velocity was obtained using color-flow Doppler and continuous-wave 
Doppler (Vezzosi et al., 2018) using the left parasternal 4-chamber view optimized for the RV 
inflow tract (Kellihan and Stepien, 2012) and care was taken to align the cursor with the TR jet 
direction (Visser et al., 2016). Then, peak tricuspid regurgitation gradient (TRGP) was calculated 
using the simplified Bernoulli equation: TRPG = 4 × TR2. A peak TR velocity > 3 m/s 
corresponding to a TRPG > 36 mmHg was used to diagnose PH (Borgarelli et al., 2015). 
For RPADi, a M-mode echocardiography of the right PA using the Lx-4-chamber view was 
obtained with a fast speed in a way to acquire three cycles in a frame (Venco et al., 2014). Then, 
the minimum diastolic (PAd usually at the Q wave) and maximum systolic (PAs, usually at the T 
wave) diameter of right PA were measured using the edge to leading-edge technique with the 
cursor as perpendicular as possible with right PA. Then, RPADi was calculated by the following 
formula: RPADi = (PAs-PAd)/Pas × 100 (Visser et al., 2016) (Figure 1). 
 
Figure 1. Representative measure of the RAD (Figure A; dotted line), RVID (Figure B; dotted line), RVFW (Figure C; 
dotted line), RVAs (Figure D; dotted dashed), RVAd (Figure E; dotted dashed) and PA (Figure F; dotted lines) (Images 
retrieved from the echocardiograms performed in HVP). 
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3. STATISTICAL ANALYSIS 
Statistical analysis was performed using a commercially available statistical software 
package (GraphPad Prism, version 7.04, San Diego, CA, USA) and in all cases a value of P < 
0.05 was considered statistically significant. Descriptive statistics were generated, and the 
Shapiro-Wilk normality test was used to verify normal distribution of variables. Continuous data 
are reported as mean ± standard deviation (SD) and categorical data like age, weight, gender 
(coded as female= 0 male= 1) as a median and range (minimum-maximum). 
 Comparisons between the 3 studied groups were performed using one-way analysis of 
variance (ANOVA) or the Kruskal-Wallis test. One-way ANOVA was used to compare continuous, 
normally distributed data, with posthoc comparisons performed using Tukey’s test. The Kruskal-
Wallis test was used to compare ordinal and continuous, non-normally distributed data, with 
posthoc comparisons performed using Dunn’s method. 
Unpaired t-test was performed to compare between 2 groups of independent samples. In 
this study, we compared the TR in the Asymptomatic HCM and HCM+CHF groups. Pearson 
correlation was used to determine the strength of association between PAPs and RPADi, FAC 
and RV MPI after normality testing and both PAP and RPADi, FAC, RV MPI values from the study 
populations followed a Gaussian distribution. 
From the cats in the control group, reference intervals for RVFWd, MAPSE IVS, TAPSE, 
RPADi and RV MPI were generated using the upper and lower limits on the distribution estimated 
with a 90% confidence interval (CI). 
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V. RESULTS 
1. SAMPLE CHARACTERIZATION – CAT POPULATION  
1.1. Gender, Age, Body Weight, Breed  
From September 2017 to March 2018, 27 cats were included in the study, although 2 of 
these cats were subsequently excluded because they did not meet the defined inclusion criteria. 
Therefore, the population of cats evaluated (n=25) included: 7 cats in the control group, 9 in the 
asymptomatic HCM group and 9 in the HCM+CHF group. From this population, there were 12 
males (most of them in the Asymptomatic HCM group (n=8)) and 13 females, with 6 in the control 
and HCM+CHF group and 1 in the asymptomatic HCM group. 
The median body weight of the population was 3.48 (2.3-5.35) kilograms, the median age 
was 5.00 (0.3-20) years, and the median heart rate was 214 (140-263) beats per minute. With 
respect to body weight and heart rate there was no statistically significant (P>0.05) difference 
between groups. Age was significantly greater (P<0.01) in the HCM+CHF group, as compared to 
control group (Figure 2 and Table 1). 
  
Figure 2. Box and whisker plot for body weight, age and heart rate in control cats, asymptomatic HCM cats and cats 
with HCM+CHF. **P < 0.01. 
 The majority of cats were European shorthair (n=18), followed by Persian (n=4), Siamese 
(n=2) and Sphynx (n=1). The control group had 7 European shorthair, the asymptomatic HCM 
group had 5 European Shorthair, 1 Sphynx and 3 Persian and the HCM+CHF group had 6 
European Shorthair, 2 Siamese and 1 Persian. Only one cat was sedated with butorphanol. A 
summary of the demographic data is presented in Table 1 and a summary of the clinical record 
results of the HCM group is presented in Appendix II. 
Table 1. Clinical data of all studied cats (n=25). Bolded values denote statistical significance. 
a P < 0.05 as compared to control. 
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 Control (n=7) Asymptomatic HCM (n=9)  HCM+CHF (n=9) P Value 
Body weight (Kg) 3.35 ± 1.03 3.62 ± 0.95 3.82 ± 0.71 0.572 
Age (years) 1.67 ± 1.61 6.94 ± 6.55 10.94 ± 5.66a 0.008 
Heart Rate (bpm) 209.90 ± 39.58 211.80 ± 26.94 202.30 ± 35.30 0.826 
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2. ECHOCARDIOGRAPHIC DATA 
A summary of the echocardiographic data is presented in Appendix III. When comparing 
the 3 groups, cats with HCM+CHF had significantly (P<0.01) lower MAPSE IVS (a LV function 
index) than control and asymptomatic groups. However, when comparing MAPSE IVS of the 
asymptomatic HCM cats with the control group, values were not significantly different (P>0.05). 
TAPSE, a RV function index, was significantly decreased (P<0.01) in cats in the HCM+CHF group 
compared with asymptomatic HCM cats. Despite that, when comparing TAPSE of the HCM+CHF 
and asymptomatic HCM cats with the control group it was not significantly different (P>0.05) 
(Figure 3). Reference intervals for MAPSE IVS and TAPSE were generated from the control group 
(Table 2). 
 
Figure 3. Box and whisker plots for MAPSE IVS and TAPSE in control cats, asymptomatic HCM cats and cats with 
HCM+CHF. **P < 0.01. 
Table 2. Distribution of data for MAPSE IVS and TAPSE in 7 healthy cats. 
 
MAPSE IVS  TAPSE 
Mean (mm) 4.70 6.56 
Standard deviation 0.59 1.50 
Reference interval (CI=90%) 4.27- 5.13 5.46 - 7.66 
Minimum  4.2 4.6 
Maximum 5.8 8.5 
Left atrial size, as evaluated by LAD and LAD/Ao was significantly higher in cats in the 
HCM+CHF group compared with control (P<0.01) and asymptomatic HCM groups (P<0.05 and 
P<0.01, respectively) (Figure 4). 
 
Figure 4. Box and whisker plots for LA size (LAD, LAD/Ao) assessment in control cats, asymptomatic HCM cats and 
cats with HCM+CHF. *P < 0.05; **P < 0.01. 
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The LV size indices (LVIDd and LVIDs) did not differ significantly (P>0.05) among any of 
the groups. LVPWd was significantly (P<0.01) increased in cats with HCM+CHF compared with 
the control group. LVPWs was also significantly (P < 0.01) higher in HCM groups (Asymptomatic 
and CHF) compared with the control group. Both IVSd and IVSs were significantly increased in 
asymptomatic cats (P<0.01) and cats with HCM+CHF (P<0.05) compared with the control group. 
There were no statistically significant (P>0.05) differences for the LV function indices (LV EF and 
LV FS) among the groups (Figure 5). 
 
Figure 5. Box and whisker plots of LV size and function indices in control cats, asymptomatic HCM cats and cats with 
HCM+CHF. *P < 0.05; **P < 0.01. 
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There were no significant (P>0.05) differences in the aortic flow between groups, except 
when comparing the asymptomatic HCM group with the control where there was a significative 
increase (P<0.01) in aortic velocity and velocity gradient. The pulmonary flow was not significantly 
(P>0.05) different between groups except for the HCM+CHF group, where there was a 
significative decrease (P<0.05) of the pulmonary velocity gradient compared with the 
asymptomatic HCM group (Figure 6). 
 
Figure 6. Box and whisker plots for aortic velocity and gradient and for pulmonary velocity gradient in control cats, 
asymptomatic HCM cats and cats with HCM+CHF. *P < 0.05. 
For mitral inflow there were no significant differences (P>0.05) among the groups for the 
E wave (velocity and gradient), A wave (velocity and gradient) and E:A ratio. Tricuspid flow was 
also assessed and there were no significant differences (P>0.05) between groups for the E wave 
(velocity and gradient), A wave (velocity and gradient) and E:A ratio. 
Concerning right heart size indices (RVIDd, RVDd, RAD), there were no statistically 
significant differences (P>0.05) between groups, except for RVFWd, which was significantly 
greater in the HCM+CHF group (P<0.05) than in the control group. RV function indices (RV FS, 
RV FAC) were significantly (P<0.05) decreased in cats in the HCM+CHF group compared with 
asymptomatic HCM cats. However, when comparing these RV function indices of HCM+CHF and 
asymptomatic HCM cats with the control group there were no significant differences (P>0.05). 
There was no statistically significative difference in RVIDs, between the different groups. When 
RVFWd was indexed to body weight (iRVFWd) to rule out an effect of body size on RVFWd, there 
were no statistically significant differences (P>0.05) between the 3 groups (Figure 7). The 
reference interval for RVFWd is presented in Table 3. From the HCM cats (asymptomatic and 
CHF) just one cat in the asymptomatic HCM group had an RVFWd > 3.2 mm. The value 3.2 mm 
corresponds to the maximum value of RVFWd in healthy cats, and above this threshold cats were 
diagnosed with RV hypertrophy. 
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Figure 7. Box and whisker plots for RV size and function indices (RVID, RVD, RAD, RVFWd, iRVFWd, RV FS, RV 
FAC) in control cats, asymptomatic HCM cats and cats with HCM+CHF. *P < 0.05. 
Table 3. Distribution of data for RV MPI, RPADI and RVFWd in 7 healthy cats. 
 
 
 
 
TDI of RVFW myocardial systolic (S’) and diastolic (E’, A’) velocities were not significantly 
different (P>0.05) between the three groups (Figure 8). 
 
Figure 8. Box and whisker plots for TDI of RVFW myocardial systolic and diastolic velocities in control cats, 
asymptomatic HCM cats and cats with HCM+CHF. 
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RV MPI RPADi RVFWd 
Mean (mm) 0.28 24.42 1.94 
Standard deviation 0.21 11.04 0.65 
Reference interval (CI=90%) 0.10-0.45 16.31-32.53 1.47-2.42 
Minimum  0.05 4 1.2 
Maximum 0.62 37.93 3.2 
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For RV MPI and RPADi, there were no statistically significant differences (P>0.05) 
between the different groups. Reference intervals for these indices were generated (see Table 
3). There were no statistically significant (P>0.05) differences in TR velocity and gradient (TRPG) 
between groups. Only two cats in the study (from the HCM+CHF group) were diagnosed with PH 
(prevalence of 8%), one with a TRGP of 36 mmHg (mild PH) and another with 49 mmHg 
(borderline to moderate PH) (Figure 9). 
 
Figure 9. Scatter dot plots of TR and TRPG in the HCM group (Asymptomatic and HCM + CHF). For each group bars 
and error bars represent mean and standard deviation. The dotted lines represent the different reference value to 
classify the severity of PH (Diagnosis of PH: TRGP= 36 mmHg, mild PH: 36-50 mmHg, moderate PH= 50-75 mmHg 
and severe PH ≥ 75 mmHg). 
The results of the correlation between echocardiographic indices (RPADi, RV MPI, RV 
FAC, TDI RVFW S’) and TRPG used to estimate PAPs are presented in Table 4. Based on the 
Pearson correlation, these indices did not exhibit significant (P>0.05) correlations with estimated 
PAPs to predict severity of PH. There is a tendency for RPADi, TDI RVFW S’ and RV FAC to 
decrease when PAPs increase and a tendency for RV MPI to increase when PAPs increase, 
although these correlations cannot be interpreted with confidence (Figure 10). 
Table 4. Results of Pearson correlation for the prediction of HP severity via TRPG to estimate PAPs. 
Pearson correlation  
 r 95% CI of r R
2 P Value  
RPADi - 0.64 -0.94 to 0.22 0.41 > 0.05 
RV MPI 0.22 -0.72 to 0.88 0.05 > 0.05 
RV FAC - 0.63 -0.94 to 0.23 0.40 > 0.05 
TDI RVFW S' - 0.18 -0.82 to 0.67 0.03 > 0.05 
     r- correlation coefficient, R 2- coefficient of determination, CI- confidence interval  
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Figure 10. Scatter plots illustrating no significant differences (P>0.05) in correlations (r) between systolic pulmonary 
arterial pressures (PAPs) estimated by Doppler echocardiography of TRGP and 4 indirect indices to predict severity of 
pulmonary hypertension: RV FAC, RPADi, TDI RVFW S’ and RV MPI in the group of cats with HCM+CHF. 
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VI. DISCUSSION 
On the left side of the heart, IVSd and IVSs were both increased in cats with HCM 
(asymptomatic and the ones with CHF) compared with healthy control cats. The LVFWd and 
LVFWs were also increased in cats with CHF secondary to HCM compared to the control group 
and LVFWs was also increased in the asymptomatic HCM cats when compared with the control 
group. The increased LV indices (IVSd and LVFWd) support the diagnosis of HCM. HCM is 
characterized by a concentric myocardial hypertrophy that may be generalized or affects certain 
segments like the interventricular septum or the free wall (IVSd and LVFWd ≥ 6 mm) or papillary 
muscles (Trehiou-Sechi et al., 2012; Smith et al., 2016; Visser et al., 2015). 
In this study, as in previous studies that assessed LA size and function, cats with HCM 
that developed CHF had an increased LAD (18.1 ± 5.21 mm) and LAD/Ao (2.30 ± 0.75) in 
comparison with the asymptomatic HCM group and the control group. These findings reflect the 
progression of diastolic dysfunction that leads to an increased LV diastolic filling pressure and 
consequently an elevation of LA pressure (LA enlargement: LA/Ao > 1.6). Therefore, it is 
important to evaluate LA size and function by echocardiography because these indices have a 
clinical and prognostic value that is already well described in the literature (Visser et al., 2017; 
Spalla et al., 2017; Linney et al., 2014; Payne et al., 2013). LA dilation increases the risk of ATE 
(White, 2015) and is associated with decreased survival times in HCM cats (Linney et al., 2014). 
In a recent study MAPSE and TAPSE values decreased in cats with HCM, as compared 
to control healthy cats and were lowest in CHF group; these findings suggest the presence of 
systolic longitudinal dysfunction in cats with HCM (Spalla et al, 2017). Similarly, the results of the 
present study indicate that cats with CHF secondary to HCM have the lowest MAPSE values, as 
compared to asymptomatic and control cats. On the other hand, cats with CHF had lower values 
of TAPSE when compared with the asymptomatic group but no significant differences were 
observed when comparing the CHF and asymptomatic group with the control group. In fact, if we 
compare the values of TAPSE obtained in control cats in our study and the study by Spalla et al. 
(2017), these values are lower in the current work, so it would be important to increase sample 
size to consolidate these results. Differences in heart rate should also be considered, as TAPSE 
is affected by this parameter (Hamilton-Craig et al., 2016). A major component of cardiac 
contraction is the shortening of the ventricle in a longitudinal axis from the base to the apex as 
the heart contracts. Both MAPSE and TAPSE measure this longitudinal AV plane displacement 
and, for this reason, they work as a marker of systolic long axis function. In humans, up to 60% 
of the total cardiac stroke volume is due to shortening of the LV in the longitudinal axis (Spalla et 
al., 2017). Our study demonstrates, as mentioned before, that cats with HCM have lower MAPSE 
compared with healthy cats, confirming reduced systolic longitudinal function. These changes in 
LV function are expected in HCM, but this study also demonstrates that RV longitudinal 
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displacement is reduced in HCM cats with CHF compared with asymptomatic cats. This might be 
explained by left-sided heart diseases that provoke RV functional abnormalities due to PH or 
alterations in RV coronary perfusion pressure or decreased RV compliance due to the ventricular 
interdependence that occurs in advanced stages of HCM disease, namely CHF. In human 
medicine, TAPSE is also decreased in HCM but RV hypertrophy as a cause for that finding is not 
clear (Spalla et al., 2017). Another interesting finding is that the lowest values of TAPSE and 
MAPSE are present in cats with CHF, which may reflect the progression of HCM and worsening 
systolic dysfunction. So, MAPSE and TAPSE may have potential prognostic value in cats with 
HCM (see Appendix IV to compare the reference values obtained in this study compared to Spalla 
et al., 2017). 
The aortic flow (velocity and velocity gradient) was higher in the asymptomatic cats when 
compared with the control group. This may be explained by the presence of LVOTO in some of 
the asymptomatic cats (n=5), which could affect the estimation of aortic flow. LVOT caused by 
SAM causes a dynamic obstruction to the ejection of blood into the aorta (Côté et al., 2011), which 
might provoke an increased flow through the aorta. The pulmonary artery velocity gradient was 
diminished in cats with HCM + CHF compared with asymptomatic cats, but no difference was 
observed between HCM + CHF group and the control group. An interesting finding is that the 
HCM cats with the highest pulmonary velocity gradients had RVOTO. This obstruction to the 
ejection of blood into the pulmonary artery might explain why cats with RVOTO have a higher 
pulmonary velocity gradient. 
Recently, studies that assess right heart size and function in cats with HCM have been 
performed. Similar to the findings of Schober et al. (2016) and Visser et al. (2017), we also found 
it difficult to assess the RV because of its small size and geometric complexity. 
The results of our prospective study support the hypothesis that RV dysfunction occurs in 
some cats with HCM. RV hypertrophy inferred using RVFWd indices was significantly higher in 
some cats with HCM (with CHF) (2.83 ± 0.58) compared with control cats (1.94 ± 0.65). From the 
HCM cats (asymptomatic and CHF) just one cat in the asymptomatic HCM group had an RVFWd 
> 3.2 mm. In Visser et al. (2017), the cut-off value for RV hypertrophy was RVFWd > 3.5 mm. 
However, conclusions about the clinical status or severity of the disease cannot be made because 
there was no significant difference in RV wall thickness when comparing the CHF group with the 
asymptomatic group. In our study, there were also no significant differences in RA and RV 
chamber dilation, as stated in Visser et al. (2017) which may be explained by the low sample size. 
This study also supports the finding that not all the HCM cats have RV involvement as 
reported by Visser et al. (2017) and Schober et al. (2016). This finding can be explained by many 
reasons, including the lack of accuracy of the echocardiography measurement, the development 
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of the hypertrophy associated with a severe stage of the disease, or phenotypic diversity of HCM 
(just thickened in some cats with myocardial hypertrophy) (Visser et al., 2017).  
The RV function indices (RV FS and RV FAC) were significantly decreased in cats with 
CHF secondary to HCM compared with the asymptomatic cats. RV FS and RV FAC are indices 
of RV systolic function: RV FS measures the percentage change in RV size between filling and 
emptying and RV FAC measures the change in RV area. They are correlated with RV ejection 
fraction (that measures the volume leaving the RV). In cases of CHF, the elevated right-sided 
diastolic pressures lead to increased RV ventricular and atrial dilation, decreasing systolic 
function and consequently the ejection fraction, which may explain why RV FS and RV FAC are 
decreased in cases of HCM with CHF.  
In the literature, it is reported that RV FAC is decreased in dogs (Visser, 2017) and in 
humans with severe PH (Boon, 2011). This makes sense because PH can be a consequence of 
CHF. We also evaluated the correlation between RV FAC and estimated PAPs to predict severity 
of PH and, although it did not exhibit a significant correlation, we observed a tendency of RV FAC 
to decrease as PAPs increased, which is what is described in the literature for dogs with PH 
(Visser, 2017; Visser et al., 2017).  See Appendix IV to compare the reference values obtained in 
this study compared to Visser et al., 2017). 
  RPADi, RV MPI and TDI RVFW S’ indices have been studied in dogs, although to our 
knowledge, there are no studies that have evaluated these indices in cats with CHF secondary to 
HCM. Apart from measuring these indices, we correlated them with PAPs to predict the severity 
of PH. Although RPADi, RV MPI and TDI RVFW S’ did not exhibit a significant correlation, we 
observed a tendency of RPADi and TDI RVFW S’ to decrease when PAPs increase and a 
tendency of RV MPI to increase when PAPs increase. Despite these correlations did not achieve 
statistical significance the results obtained here are in line with what is described in the literature 
for dogs with PH (Kellihan and Stepien, 2012; Venco et al., 2014; Visser et al., 2016; Visser, 
2017). 
RPADi is a valuable method for early detection of the presence and severity of PH (Venco 
et al., 2014; Visser et al., 2016), and in dogs a normal pulmonary pressure is correlated with a 
RPADi ≥36% (Serrano-Parreño et al., 2017). A decrease in RPADi (< 35% in dogs) can be an 
indicative of PH. RV MPI is an index of global myocardial function of the RV (Boon, 2011) and is 
also a valuable indicator of PH (Venco et al., 2014). Augmented values of RV MPI may support 
the diagnosis of PH (>0.25 for dogs) (Kellihan and Stepien, 2012) and are associated with RV 
myocardial dysfunction when changes in load are chronic (Boon, 2011; Visser, 2017). TDI of the 
lateral tricuspid annulus allows the assessment of RVFW myocardial systolic function and 
reductions in this indice are associated with decreased RV ejection fraction in humans (Boon, 
2011; Cincin et al., 2015) and in cases of PH in dogs (Kellihan and Stepien, 2012). 
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PH is a respiratory vascular disorder that is less commonly recognized in cats than in 
dogs. It is also unclear whether the development of PH might affect the prognosis of an animal 
with cardiopulmonary disease (Boon, 2011). To understand this condition, an assessment of the 
RV is required to diagnose the pathology. After diagnosing PH, it will be possible to start 
developing new strategies and trials in order to treat the disease. In this study, two cats had PH 
(prevalence = 8 %). This low percentage may be expected due to the low sample size, as an 
insufficient or small sample size may not be able to show the desired difference or to estimate the 
frequency of the event with acceptable accuracy (Martínez-Mesa et al., 2014). Hence, further 
studies in cats are necessary to investigate the real prevalence of this disease, to ameliorate the 
knowledge of this pathology and to discover its impact on survival. 
This study has several limitations, with the most important being sample size. A small 
sample may not detect important results because the study lacks precision and power (Houe et 
al., 2004); this may explain the lack of significant differences between groups for some indices. 
Another limitation is the discrepancy in the age range between the control cats, which were much 
younger than the HCM (asymptomatic and CHF) cats and this could result in errors in the 
statistical analysis. Besides that, we did not evaluate the influence of medications like furosemide 
that reduce preload and may influence echocardiographic measurements, especially those that 
evaluate longitudinal function (MAPSE, TAPSE and TDI). We also tried to exclude all possible 
secondary causes of LV hypertrophy, but we could not rule out rare causes of myocardial 
hypertrophy such as transient myocarditis. 
Another limitation was that PAH was classified based on TRPG and not by invasive 
measurements of pulmonary artery systolic pressures for right heart catheterization, which is the 
gold standard method. In veterinary medicine, this is an invasive and expensive diagnostic test, 
which is why we used TRPG and measured RPADi. A recent study showed that RPADi has a 
strong correlation with invasive “gold standard” systolic PA pressures and it might be valuable to 
start applying this method in combination with TRPG to diagnose PH (Visser et al., 2016). Also 
the cut-off value of TRGP established as 36 mmHg to diagnose PAH is based on the studies of 
Vezzosi et al. (2018) and Visser et al. (2016) and is not consensual in the literature; a slightly 
different cut-off may have altered our results. 
Finally, there are also some limitations in terms of the accuracy of measurements because 
they may be affected by a certain degree of misalignment. We found it difficult to measure the 
diameter of the right pulmonary artery because the dimension of this artery in cats is much smaller 
than in dogs. This might introduce some lack of accuracy to RPADi measurements. Also, it was 
difficult to obtain a good profile of tricuspid inflow due to the high heart rate of the cats, which may 
be stressed by the echocardiographic examination. This led to difficulties in calculating the time 
from closure to opening of the tricuspid valve to apply in the RV MPI formula.  
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VII. CONCLUSION 
 In this study, right heart size (RVFWd) was significantly increased in cats with HCM and 
CHF compared to the control group and several parameters of RV function (RV FAC, RV FS and 
TAPSE) were significantly decreased in the HCM group with CHF compared with asymptomatic 
HCM group. 
The abnormalities in RV size and function support the hypothesis that in cats with HCM 
the RV is involved as well as the LV. The fact that some cats had an increased wall thickness 
supports other studies, in which the same finding was observed. Also, it highlights the importance 
of echocardiographic evaluation of RV size and function. 
 Cats with HCM had lower MAPSE IVS and the lowest values were in cats with CHF for 
both MAPSE IVS and TAPSE. Therefore, TAPSE and MAPSE are useful indices to evaluate 
longitudinal myocardial function in cats with HCM and should be measured on routine 
echocardiographic examination. 
In cats as in dogs, PH can occur and in this study 8% of the cats from the HCM+CHF 
group developed PH as a complication of CHF.  
RPADi, RV FAC, RV MPI and TDI RVFW S’ did not exhibit a significant correlation when 
compared with PAPs, but tendencies for RPADi, TDI RVFW S’ and RV FAC to decrease when 
PAPs increase and for RV MPI to increase when PAPs increase were observed. 
 Further prospective studies with a larger sample size are required to verify the real 
prevalence of PH in cats with HCM and evaluate whether RPADi, RV MPI, TDI RVFW S’ and RV 
FAC to assess RV function might add clinical value and predict the severity of PH in cats with 
HCM. 
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IX. APPENDIX 
APPENDIX I 
Model of the questionnaire used for the clinical record of the cats enrolled in the study.  
 
II 
 
APPENDIX II 
Summary of the clinical record results obtained with the questionnaire presented in Annex I. 
 
Finding Asympt. HCM (n=9)  HCM+CHF (n=9) % of all HMC cats with the finding 
Murmur 7 6 72% 
SAM 2 1 17% 
LVOTO 5 2 39% 
RVOTO 1 2 17% 
PH  0 2 11% 
Ascites 0 1 6% 
Pulmonary oedema 0 6 33% 
Pleural effusion 0 3 17% 
Mild pericardial effusion 0 1 5% 
ATE 0 1 5% 
 
III 
 
APPENDIX III 
Summary of the echocardiographic data evaluated in this study. 
 
Control (n=7) Asymptomatic HCM (n=9) HCM+CHF (n=9) P value 
Left heart 
    
IVSd (mm) 3.90 ± 1.05 6.58 ± 1.25 6.00 ± 1.45a,b 0.0039 
IVSs (mm) 6.03 ± 0.49 8.90 ± 2.01 8.06 ± 1.88a,b 0.0045 
LVIDd (mm) 13.23 ± 2.86 14.30 ± 3.54 14.28 ± 3.52 0.7804 
LVIDs (mm) 6.64 ± 2.42 6.33 ± 2.70 7.76 ± 3.23 0.5482 
LVFWd (mm) 4.01 ± 0.57 5.10 ± 1.27 6.67 ± 1.97a 0.0048 
LVFWs (mm) 6.07 ± 0.45 8.36 ± 1.09a 8.61 ± 1.71a 0.001 
LV SF (%) 50.00 ± 10.85 56.22 ± 14.29 46.00 ± 16.87b 0.3395 
LV EF (%) 83.43 ± 9.29 86.78 ± 13.19 77.11 ± 21.16 0.2576 
MAPSE IVS (mm) 4.70 ± 0.59 4.38 ± 0.87 2.76 ± 0.88a,b 0.0001 
LAD (mm) 9.46 ± 1.12 13.41 ± 2.12 18.07 ± 5.21a,b 0.0002 
LAD/Ao (mm) 1.30 ± 0.10 1.51 ± 0.29  2.30 ± 0.75 0.0009 
Mitral E (m/s) 0.71 ± 0.17 1.01 ± 0.28 1.02 ± 0.45 0.1437 
Mitral E (mmHg) 2.13 ± 1,01 4.38 ± 2.19 4.85 ± 3.79 0.1322 
Mitral A (m/s) 0.36 ± 0.27 0.33 ± 0.42 0.20 ± 0.27  0.5822 
Mitral A (mmHg) 0.77 ± 0.66 1.04 ± 1.57 0.43 ± 0.72 0.5822 
Mitral E/A 0.95 ± 0.70 0.62 ± 0.84 0.83 ± 1.21 0.5636 
Aor (m/s) 0.89 ± 0.11 2.05 ± 1.20a 1.83 ± 1.41 0.0327 
Aor (mmHg) 3.19 ± 0.81 21.88 ± 28.56a 20.40 ± 28.18 0.0327 
Right Heart     
RVDd (mm) 2.69 ± 0.87 2.87 ± 1.57 3.88 ± 3.00 0.4621 
RVIDd (mm) 4.60 ± 1.27 5.21 ± 1.76 5.79 ± 2.68 0.6750 
RVIDs (mm) 1.74 ± 0.71 1.48 ± 0.74 3.02 ± 2.28 0.0908 
RV FS (%) 60.33 ± 16.19 71.78 ± 7.22 52.56 ± 19.22 0.04 
RADs (mm) 7.84 ± 1.66 7.39 ± 2.27 10.26 ± 4.15 0.1191 
RADd (mm) 10.17 ± 1.28 10.82 ± 2.17 11.11 ± 4.43 0.8270 
RVFWd (mm) 1.94 ± 0.65 2.49 ± 0.65 2.83 ± 0.58a 0.032 
iRVFWd 0.64 ± 0.32 0.68 ± 0.14 0.78 ± 0.23 0.4783 
TAPSE (mm) 6.56± 1.50 8.49 ± 1.20 5.06 ± 1.66b 0.0008 
RV FAC (%) 76.07 ± 13.07 79.53 ± 8.92 58.89 ± 20.89b 0.0215 
RPADi (%) 24.42 ± 11.04 25.09 ± 17.08 20.73 ± 7.79 0.7431 
RV MPI 0.28 ± 0.21 0.64 ± 0.32 0.33 ± 0.20 0.0501 
TDI S' RVFW (m/s) 0.11 ± 0.02 0.11 ± 0.02 0.09 ± 0.03 0.1736 
TDI E RVFW (m/s) 0.11 ± 0.05 0.12 ± 0.06 0.08 ± 0.05 0.1753 
TDI A RVFW (m/s) 0.09 ± 0.02 0.14 ± 0.06 0.09 ± 0.03 0.0785 
Tricusp. E (m/s) 0.63 ± 0.07 0.67 ± 0.14 0.56 ± 0.18 0.2791 
Tricusp. E (mmHg) 1.59 ± 0.37 1.86 ± 0.79 1.36 ± 0.81 0.3409 
Tricusp. A (m/s) 0.40 ± 0.07 0.55 ± 0.20 0.42± 0.25 0.2511 
Tricusp. A (mmHg) 0.67 ± 0.23 1.67 ± 1.72 0.93 ± 1.20 0.2266 
Tricusp. E/A 1.58 ± 0.21 1.28 ± 0.41 1.62 ± 0.80 0.3888 
TR (m/s) 
 1.47 ± 0.33 2.07 ± 1.12 0.2753 
TRPG (mmHg) 
 9.01 ± 4.07 21.50 ± 18.32 0.1701 
Pul (m/s) 0.89 ± 0.16 1.13 ± 0.20 0.89 ± 0.23 0.0352 
Pul (mmHg) 3.29 ± 1.15 5.22 ± 1.79 3.35 ± 1.54b 0.026 
a P < 0.05 as compared to control;  
b P < 0.05 as compared to asymptomatic HCM group; 
IV 
 
APPENDIX IV 
Summary of the echocardiographic data obtained in our study and the reference values established in the literature. 
 Control healthy cats  Asymptomatic HCM cats  HCM+CHF cats  
 Our Study Literature Author Our Study Literature Author Our Study Literature Author 
Left heart    
IVSd (mm) 3.90 ± 1.05 4.20 ± 0.70  (Sisson et al., 1991) 6.58 ± 1.25 
>6 (Diagnose 
of HCM) 
(Häggström et al., 
2015) 
6.00 ± 1.45 >6 (Diagnose of HCM) 
Häggström et al., 
2015) 
IVSs (mm) 6.03 ± 0.49 6.70 ± 1.20 (Sisson et al., 1991) 8.90 ± 2.01   8.06 ± 1.88   
LVIDd (mm) 13.23 ± 2.86 
15.00 ± 2.00 (Sisson et al., 1991) 
14.30 ± 3.54 13.40 ± 1.70 (Visser et al., 2017) 14.28 ± 3.52 14.10 ± 2.60 (Visser et al., 2017) 
14.20 ± 1.80 Visser et al., 2017) 
LVIDs (mm) 6.64 ± 2.42 
7.20 ± 1.50 (Sisson et al., 1991) 
6.33 ± 2.70 5.70 ± 1.40 (Visser et al., 2017) 7.76 ± 3.23 7.60 ± 2.10 (Visser et al., 2017) 
6.70 ± 1.50 (Visser et al., 2017) 
LVFWd (mm) 4.01 ± 0.57 4.10 ± 0.70 (Sisson et al., 1991) 5.10 ± 1.27   6.67 ± 1.97   
LVFWs (mm) 6.07 ± 0.45 6.80 ± 1.10 (Sisson et al., 1991) 8.36 ± 1.09   8.61 ± 1.71   
LV SF (%) 50.00 ± 10.85 
52.10 ± 7.11 (Sisson et al., 1991) 
56.22 ± 14.29 
57.10 ± 8.50 (Visser et al., 2017) 
46.00 ± 16.87 
45.70 ± 11.90 (Visser et al., 2017) 
53.10 ± 7.20 Visser et al., 2017) 
49.50 (45.10-
53.50)  
(Spalla et al., 2017) 
57.00 (43.10-
61.90) 
(Spalla et al., 2017) 44.80 (38.30-56.70)  (Spalla et al., 2017) 
LV EF (%) 83.43 ± 9.29 
82.28 ± 4.64 
(specific breed) 
(Noviana et al.,2013) 86.78 ± 13.19   77.11 ± 21.16   
MAPSE IVS (mm) 4.70 ± 0.59 5.22 ± 0.59 (Spalla et al., 2017) 4.38 ± 0.87 
4.70 (4.10-
5.20) 
(Spalla et al., 2017) 2.76 ± 0.88 2.60 (2.50-3.20) (Spalla et al., 2017) 
LAD (mm) 9.46 ± 1.12 
11.70 ± 1.70 (Sisson et al., 1991) 
13.41 ± 2.12 
16.0 (14.10-
17.90) 
(Spalla et al., 2017) 18.07 ± 5.21 19.90 (16.20-22.60) (Spalla et al., 2017) 14.30 (13.00-
15.30) 
(Spalla et al., 2017) 
Ao (mm)  9.50 ± 1.40 (Sisson et al., 1991)       
LAD/Ao (mm) 1.30 ± 0.10 
1.25 ± 0.18 (Sisson et al., 1991) 
1.51 ± 0.29 
1.40 ± 0.20 (Visser et al., 2017) 
2.30 ± 0.75 
2.10 ± 0.40 (Visser et al., 2017) 
1.40 ± 0.10 (Visser et al., 2017) 
1.27 (1.12-1.36) (Spalla et al., 2017) 
1.39 (1.28-
1.60) 
(Spalla et al., 2017) 
2.10 (1.80-2.39) 
 
(Spalla et al., 2017) 
 
>1.60 (LA enlargement) 
 
 
(Visser et al., 2017) 
V 
 
Mitral E (m/s) 0.71 ± 0.17 
0.67 ± 1.13 
(Santilli and 
Bussadori, 1998) 1.01 ± 0.28   1.02 ± 0.45   
0.70 ± 0.14 (Disatian et al., 2008) 
Mitral E (mmHg) 2.13 ± 1.01   4.38 ± 2.19   4.85 ± 3.79   
Mitral A (m/s) 0.36 ± 0.27 
0.59 ± 0.14 
(Santilli and 
Bussadori, 1998) 0.33 ± 0.42   0.20 ± 0.27   
0.65 ± 0.14 (Disatian et al., 2008) 
Mitral A (mmHg) 0.77 ± 0.66   1.04 ± 1.57   0.43 ± 0.72   
Mitral E/A 0.95 ± 0.70 
1.19 ± 0.30 
(Santilli and 
Bussadori, 1998) 0.62 ± 0.84   0.83 ± 1.21   
1.12 ± 0.22 (Disatian et al., 2008) 
Aor (m/s) 0.89 ± 0.11 1.1 ± 0.2 (Boon, 2011) 2.05 ± 1.20   1.83 ± 1.41   
Aor (mmHg) 
 
3.19 ± 0.81   21.9 ± 28.56   20.4 ± 28.18   
Right Heart   Right Heart 
RVDd (mm) 2.69 ± 0.87 0.50-6.70 (Boon, 2011) 2.87 ± 1.57   3.88 ± 3.00   
RVIDd (mm) 4.60 ± 1.27 
4.60 ± 1.70 (Sisson et al., 1991) 
5.21 ± 1.76 6.50 ± 1.30 (Visser et al., 2017) 5.79 ± 2.68 8.00 ± 1.50 (Visser et al., 2017) 6.70 ± 1.40 (Visser et al., 2017) 
4.85 ± 1.27 (Schober et al., 2016) 
RVIDs (mm) 1.74 ± 0.71 4.30 ± 1.10  (Visser et al., 2017) 1.48 ± 0.74 3.30 ± 0.80 (Visser et al., 2017) 3.02 ± 2.28 4.80 ± 1.70 (Visser et al., 2017) 
RV FS (%) 60.33 ± 16.19 50.0 ± 8.80 (Visser et al., 2017) 71.78 ± 7.22 48.90 ± 11.20 (Visser et al., 2017) 52.56 ± 19.22 40.80 ± 13.20 (Visser et al., 2017) 
RADs (mm) 7.84 ± 1.66 
11.10 (10.10-
12.30) * 
(Visser et al., 2017) 
7.39 ± 2.27 
10.90 (10.10-
12.20) * 
(Visser et al., 2017) 10.26 ± 4.15 13.20 (12.10-14.10) * (Visser et al., 2017) 
12.71 ± 1.78 (Schober et al., 2016) 
RADd (mm) 10.17 ± 1.28   10.82 ± 2.171   11.11 ± 4.429   
RVFWd 1.94 ± 0.65 
2.40 ± 0.40 (Visser et al., 2017) 
2.49 ± 0.65 3.10 ± 0.60 (Visser et al., 2017) 2.83 ± 0.58 3.60 ± 0.90 (Visser et al., 2017) 
2.72 ± 0.52 (Schober et al., 2016) 
iRVFWd  0.64 ± 0.32 1.40 ± 0.30 (Visser et al., 2017) 0.68 ± 0.14 1.80 ± 0.30 (Visser et al., 2017) 0.78 ± 0.23 2.10 ± 0.40 (Visser et al., 2017) 
TAPSE (mm) 6.56 ± 1.50 
9.10 ± 1.40 
 
(Visser et al., 2017) 
 
 
8.49 ± 1.20 
8.50 ± 1.10 (Visser et al., 2017) 
5.06 ± 1.66 
6.50 ± 1.70 (Visser et al., 2017) 
9.02 ± 2.18  
 
 
(Spalla et al., 2017) 
 
 
7.20 (6.30-
8.20) 
(Spalla et al., 2017) 4.60 (4.10-5.40) (Spalla et al., 2017) 
VI 
 
*Median (interquartile range) presented as a result of non-Gaussian distribution; Grey boxes: Reference values for dogs. 
RV FAC (%) 76.07 ± 13.07 
63.90 ± 6.60 (Visser et al., 2017) 
79.53 ± 8.92 63.50 ± 10.40 (Visser et al., 2017) 58.89 ± 20.89 51.40 ± 14.40 (Visser et al., 2017) 46.50 ± 6.57 
(Dogs) 
 
(Visser et al., 2015) 
RPADi 24.42 ± 11.04 
45.00 ± 2.90 
(Dogs) 
 
 
(Venco et al., 2014) 25.09 ± 17.08   20.73 ± 7.79 
< 35% - Indicative of 
PH; 28- 35%- mild PH; 
23-27% - moderate PH; 
≤22 - severe PH (Dogs) 
 
(Venco et al., 2014) 
RV MPI 0.28 ± 0.21 
0.22 ± 0.10 
(Dogs) 
(Baumwart et al., 
2005) 
0.64 ± 0.32   0.33 ± 0.20 
>0.25 (Support 
diagnose of PH) 
Kellihan and Stepien, 
2012) 
TDI S' RVFW (m/s) 0.11 ± 0.02 
0.13 ± 0.04  
(Dogs) 
(Baron Toaldo et al., 
2016) 
0.11 ± 0.02   
0.09 ± 0.03 
  
TDI E RVFW (m/s) 0.11 ± 0.05 0.10 ± 0.02 (Boon, 2011) 0.12 ± 0.06   0.08 ± 0.05  
 
TDI A RVFW (m/s) 0.09 ± 0.02 1.22 ± 0.20 (Boon, 2011) 0.14 ± 0.06   0.09 ± 0.03   
Tricusp. E (m/s) 0.63 ± 0.07 0.50-0.98 (Dogs) (Boon, 2011) 0.67 ± 0.14   0.56 ± 0.18  
 
Tricusp. E (mmHg) 1.59 ± 0.37   1.86 ± 0.79   1.36 ± 0.81   
Tricusp. A (m/s) 0.40 ± 0.07 0.29-7.0 (Dogs) (Boon, 2011) 0.55 ± 0.20   0.42 ± 0.25   
Tricusp. A (mmHg) 0.67 ± 0.23   1.67± 1.72   0.93± 1.20   
Tricusp. E/A 1.58 ± 0.21 1.09-2.80 (Dogs) (Boon, 2011) 1.28 ± 0.41   1.62 ± 0.80   
TR (m/s)    1.47 ± 0.33   2.07 ± 1.12 
Evidence of PH: TR >3 
m/s (Dogs) 
(Bascuñán et al., 
2017) 
TRPG (mmHg)    9.01 ± 4.07   21.50 ± 18.32 
Diagnose of PH: TRPG 
> 36 mmHg; Mild PAH if 
TRPG:36–50 mmHg, 
moderate PAH if TRPG: 
51–75 mmHg, and 
severe PAH if TRPG 
>75 mmHg. (Dogs) 
(Borgarelli et al., 
2015) 
Pul (m/s) 0.89 ± 0.16 0.48 ± 0.14 
(Disatian et al., 2008) 
and (Boon, 2011) 
1.13 ± 0.20   0.89 ± 0.23   
Pul (mmHg) 3.29 ± 1.15   5.22 ± 1.79   3.35 ± 1.54   
VII 
 
APPENDIX V 
Representative measure of the TAPSE (Figure A; dotted line), MAPSE (Figure B; dotted line), 
Pulmonary ejection time (Figure C; red line), “x” of Tricuspid valve (Figure D; red line) and TDI 
derived peak systolic (S’) /diastolic (E/ A) longitudinal RVFW myocardial velocity / gradient (Figure 
E) (Images retrieved from the echocardiograms performed in HVP). 
 
